3,190 Shares in Amgen Inc. $AMGN Acquired by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,190 shares of the medical research company’s stock, valued at approximately $897,000.

Several other large investors have also modified their holdings of the business. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its position in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the period. Sax Wealth Advisors LLC lifted its stake in Amgen by 20.9% during the second quarter. Sax Wealth Advisors LLC now owns 1,254 shares of the medical research company’s stock worth $350,000 after purchasing an additional 217 shares in the last quarter. REAP Financial Group LLC boosted its position in shares of Amgen by 201.6% during the second quarter. REAP Financial Group LLC now owns 184 shares of the medical research company’s stock worth $51,000 after buying an additional 123 shares during the period. Finally, Bar Harbor Wealth Management boosted its position in shares of Amgen by 13.5% during the second quarter. Bar Harbor Wealth Management now owns 2,816 shares of the medical research company’s stock worth $786,000 after buying an additional 335 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

Amgen Stock Performance

Shares of AMGN opened at $367.80 on Friday. The stock has a 50-day simple moving average of $333.66 and a 200-day simple moving average of $310.84. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14. The stock has a market capitalization of $198.05 billion, a PE ratio of 25.85, a PEG ratio of 3.20 and a beta of 0.46. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $374.90.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio is presently 66.90%.

Analysts Set New Price Targets

AMGN has been the topic of several research analyst reports. Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday. Argus lifted their target price on Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research report on Tuesday, December 30th. TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Guggenheim lifted their price objective on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $347.65.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.